pharma · Monocarboxylate Transporter 8 (MCT8) deficiency
Rare Thyroid Therapeutics
Rare Thyroid Therapeutics International AB
Rare Thyroid Therapeutics is a pharma organization headquartered in Stockholm, SE. Primary therapeutic focus areas include Monocarboxylate Transporter 8 (MCT8) deficiency. NovaPharmaNews links 2 clinical program(s), 0 dr
Stockholm, SE HQ
2017 Founded
1 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Stockholm, SE
- Founded
- 2017
- Employees
- 1
- Programs
- 2
- Drugs
- 6
- Patents
- 0
Tiratricol, Tiratricol
Phase 2 · small molecule · Monocarboxylate Transporter 8 (MCT8) deficiency
Tiratricol, Tiratricol for Monocarboxylate Transporter 8 (MCT8) deficiency is a Phase 2 program (small_molecule) at Rare Thyroid Therapeutics International AB with 1 ClinicalTrials.gov record(s).
Internal code MCT8-2019-2
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Rare Thyroid Therapeutics International AB
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Monocarboxylate Transporter 8 (MCT8) deficiency
- Status
- active
- Trials
- 1